Literature DB >> 3490487

Dietary bovine antigens and immune complex formation after intravenous immunoglobulin in common varied immunodeficiency.

C Cunningham-Rundles, R I Carr.   

Abstract

Previously we have shown that the sera of hypogammaglobulinemic patients may contain large amounts of antigenically intact foreign protein of dietary origin, presumably due to the absence of an adequate gastrointestinal secretory immune barrier. In these studies we show that the intravenous infusion of immunoglobulin in these patients may result in high levels of immune complexes postinfusion and that at least one constituent of these complexes is likely to be bovine casein.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3490487     DOI: 10.1007/BF00915377

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  17 in total

1.  Immunodeficiency: report of a WHO scientific group.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1978

Review 2.  Immune complex disease in experimental animals and man.

Authors:  C G Cochrane; D Koffler
Journal:  Adv Immunol       Date:  1973       Impact factor: 3.543

3.  Detection and partial characterization of circulating immune complexes with solid-phase anti-C3.

Authors:  A B Pereira; A N Theofilopoulos; F J Dixon
Journal:  J Immunol       Date:  1980-08       Impact factor: 5.422

4.  Use of intravenous gamma-globulin in antibody immunodeficiency: results of a multicenter controlled trial.

Authors:  A J Ammann; R F Ashman; R H Buckley; W R Hardie; H J Krantmann; J Nelson; H Ochs; E R Stiehm; T Tiller; D W Wara; R Wedgwood
Journal:  Clin Immunol Immunopathol       Date:  1982-01

5.  Studies of the integrity of iodinated bovine albumin after circulating in vivo.

Authors:  W R Griswold
Journal:  Immunol Commun       Date:  1980

6.  Bovine antigens and the formation of circulating immune complexes in selective immunoglobulin A deficiency.

Authors:  C Cunningham-Rundles; W E Brandeis; R A Good; N K Day
Journal:  J Clin Invest       Date:  1979-07       Impact factor: 14.808

7.  Adverse reactions in selected patients following intravenous infusions of gamma globulin.

Authors:  N K Day; R A Good; V Wahn
Journal:  Am J Med       Date:  1984-03-30       Impact factor: 4.965

8.  Intravenous immunoglobulin therapy for antibody deficiency.

Authors:  M T Nolte; B Pirofsky; G A Gerritz; B Golding
Journal:  Clin Exp Immunol       Date:  1979-05       Impact factor: 4.330

9.  Evidence of persistent IgA/IgG circulating immune complexes associated with activation of the complement system in serum of a patient with common variable immune deficiency: anaphylactic reactions to intravenous gammaglobulin.

Authors:  V Wahn; R A Good; S Gupta; S Pahwa; N K Day
Journal:  Acta Pathol Microbiol Immunol Scand Suppl       Date:  1984

10.  Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease.

Authors:  C Cunningham-Rundles; F P Siegal; E M Smithwick; A Lion-Boulé; S Cunningham-Rundles; J O'Malley; S Barandun; R A Good
Journal:  Ann Intern Med       Date:  1984-10       Impact factor: 25.391

View more
  3 in total

1.  Complement C1q formation of immune complexes with milk caseins and wheat glutens in schizophrenia.

Authors:  Emily G Severance; Kristin L Gressitt; Meredith Halling; Cassie R Stallings; Andrea E Origoni; Crystal Vaughan; Sunil Khushalani; Armin Alaedini; Didier Dupont; Faith B Dickerson; Robert H Yolken
Journal:  Neurobiol Dis       Date:  2012-07-16       Impact factor: 5.996

2.  Long-term use of IgA-depleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies.

Authors:  C Cunningham-Rundles; Z Zhou; S Mankarious; S Courter
Journal:  J Clin Immunol       Date:  1993-07       Impact factor: 8.317

3.  Gluten-free diet exposure prohibits pathobiont expansion and gluten sensitive enteropathy in B cell deficient JH-/- mice.

Authors:  Ahmed Dawood Mohammed; Nia Hall; Ioulia Chatzistamou; Amy Jolly; Jason Lee Kubinak
Journal:  PLoS One       Date:  2022-03-24       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.